tetano
Editor, Senior Moderator
J Eur Acad Dermatol Venereol
. 2020 Nov 21.
doi: 10.1111/jdv.17045. Online ahead of print.
SARS-CoV-2-induced telogen effluvium: a multicentric study
O M Moreno-Arrones[SUP] 1 2 [/SUP], A Lobato-Berezo[SUP] 3 [/SUP], A Gomez-Zubiaur[SUP] 4 [/SUP], S Arias-Santiago[SUP] 5 [/SUP], D Saceda-Corralo[SUP] 1 2 [/SUP], C Bernardez-Guerra[SUP] 6 [/SUP], R Grimalt[SUP] 7 [/SUP], P Fernandez-Crehuet[SUP] 8 [/SUP], J Ferrando[SUP] 9 [/SUP], R Gil[SUP] 10 [/SUP], A Hermosa-Gelbard[SUP] 1 2 [/SUP], R Rodrigues-Barata[SUP] 1 2 [/SUP], D Fernandez-Nieto[SUP] 1 2 [/SUP], S Merlos-Navarro[SUP] 11 [/SUP], S Va??-Galv?n[SUP] 1 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently linked to dermatologic manifestations and is thought to affect more severely patients with androgenetic alopecia. We designed a prospective multicentric study which enrolled patients from March to August of 2020 with acute telogen effluvium (ATE) that had a prior SARS-CoV-2 infection confirmed either by serological tests (e.g. detection of serum antibodies against the virus via enzyme-linked immunosorbent assays (ELISA)) or detection of viral RNA using real-time reverse transcription polymerase chain reaction (RT-PCR).
Keywords: SARS-CoV-2; telogen effluvium.
. 2020 Nov 21.
doi: 10.1111/jdv.17045. Online ahead of print.
SARS-CoV-2-induced telogen effluvium: a multicentric study
O M Moreno-Arrones[SUP] 1 2 [/SUP], A Lobato-Berezo[SUP] 3 [/SUP], A Gomez-Zubiaur[SUP] 4 [/SUP], S Arias-Santiago[SUP] 5 [/SUP], D Saceda-Corralo[SUP] 1 2 [/SUP], C Bernardez-Guerra[SUP] 6 [/SUP], R Grimalt[SUP] 7 [/SUP], P Fernandez-Crehuet[SUP] 8 [/SUP], J Ferrando[SUP] 9 [/SUP], R Gil[SUP] 10 [/SUP], A Hermosa-Gelbard[SUP] 1 2 [/SUP], R Rodrigues-Barata[SUP] 1 2 [/SUP], D Fernandez-Nieto[SUP] 1 2 [/SUP], S Merlos-Navarro[SUP] 11 [/SUP], S Va??-Galv?n[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33220124
- DOI: 10.1111/jdv.17045
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently linked to dermatologic manifestations and is thought to affect more severely patients with androgenetic alopecia. We designed a prospective multicentric study which enrolled patients from March to August of 2020 with acute telogen effluvium (ATE) that had a prior SARS-CoV-2 infection confirmed either by serological tests (e.g. detection of serum antibodies against the virus via enzyme-linked immunosorbent assays (ELISA)) or detection of viral RNA using real-time reverse transcription polymerase chain reaction (RT-PCR).
Keywords: SARS-CoV-2; telogen effluvium.